Komori
Chordia Therapeutics (190A) · RiskMitigated

Operating Loss, Continued Negative Operating Cash Flow, and Reliance on Additional Financing

First written in FY2024. 3 of 8 entries say "Mitigated", first in FY2026-H1. Latest entry: 2026-10-15.

8entries
3years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024WorsenedFY2025-H1OtherFY2025MitigatedFY2026-H1 – 2026-07-152024: 120242025: 220252026: 52026
Same theme, other companies
Cash Management and Business Continuity Risk from Negative Operating Cash FlowA theme 15 companies write about · 15 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 6 of 12 companies on the "Worse" side.

5 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 15 companies compared. The sentences above are computed from all 15.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1MitigatedAnnual report

    「As of the end of the interim accounting period, we held ¥2,447 million in cash and deposits, securing the funds necessary to continue business activities for the next year. In September 2025, we also issued the ninth series of stock acquisition rights through a third-party allotment, with a clause for adjustment of the exercise price, as well as the tenth and eleventh series of stock acquisition rights, to secure future development funding for rogocekib. Exercise of the ninth series of stock acquisition rights is progressing. This enables us to maintain a structure capable of responding flexibly to future funding needs. Accordingly, we recognize that no material uncertainty exists regarding the going-concern assumption.」

    Although negative cash flow from operating activities continues, ¥2,447 million in cash secures the funds required for the next year, and exercise of the stock acquisition rights is progressing. The company stated that it recognizes no material uncertainty regarding the going-concern assumption, providing a specific response to recent liquidity risks.
  2. FY2025Continued negative full-year operating cash flowAnnual report

    「At our company, operating cash flow was negative at ¥1,836 million for the current fiscal year, and we expect it to remain negative from the following fiscal year onward. Accordingly, until our products are brought to market and stable sources of revenue are secured, we may need to raise additional funds as necessary to strengthen our financial base.」

    Negative operating cash flow narrowed from ¥1,937 million in the previous fiscal year to ¥1,836 million, but negative cash flow is expected to continue from the following fiscal year onward, and events or circumstances that raise substantial doubt about the going-concern assumption were described.
  3. FY2025-H1WorsenedAnnual report

    「During the interim accounting period, cash used in operating activities was ¥1,114 million, compared with ¥1,052 million used in the same interim period of the previous year.」

    Negative cash flow from operating activities increased from ¥1,052 million in the same interim period of the previous year to ¥1,114 million, while cash and cash equivalents decreased by ¥1,053 million from the beginning of the period.
  4. FY2024First statedAnnual report

    「The figure was negative at ¥1,937 million for the current fiscal year, and we expect it to remain negative from the following fiscal year onward. Accordingly, until our products are brought to market and stable sources of revenue are secured, we may need to raise additional funds as necessary to strengthen our financial base.」

    Operating cash flow was negative at ¥1,937 million, and the possibility that additional financing may be required was disclosed because negative cash flow is expected to continue from the following fiscal year onward.
Moved together

"Progress in the Phase 1/2 clinical trial of CTX-712 for blood cancer in the United States" moved the same way as this thread, in the same document, in 3 of its 8 moves.

33222★12345
  1. ★This thread
  2. 1Progress in the Phase 1/2 clinical trial of CTX-712 for blood cancer in the United States3×
  3. 2Expansion of composition-of-matter and biomarker patents in the drug discovery pipeline3×
  4. 3Report on the Clinical Efficacy of CTX-712 in Ovarian and Hematologic Cancers2×
  5. 4Funding Working Capital and Capital Expenditures with Internal Funds or Equity Financing2×
  6. 5Conduct license negotiations for marketing rights outside Japan once the results of Phase 2 clinical trials can be confirmed2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview It last moved in the Presentation materials on financial results of 2026-10-15: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.